A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506582-58-00

Acronym

75276617ALE1002

Enrollment

Registered

2024-03-18

Start date

2022-07-21

Completion date

Unknown

Last updated

2025-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

1. Incidence and severity of AEs, including DLTs, 2. Incidence and severity of Aes

Interventions

DRUGCitarabina Hikma 2 g/20mL Soluzione Iniettabile

DRUGIdarubicin Hikma 1 mg/ml Injektionslösung

DRUGCytarabine 100 mg/ml Solution for Injection or Infusion

DRUGDaunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

DRUGJNJ-75276617

DRUGJNJ-75276617 (G022)

DRUGVenclyxto 100 mg film-coated tablets

DRUGIdarubicin

DRUGJNJ-75276617 (G023)

DRUGAzacitidine

DRUGCitarabina Hikma 500mg/5mL Soluzione Iniettabile

DRUGJNJ-75276617 (G021)

DRUGJNJ-75276617 (G007)

DRUGVenclyxto 50 mg film-coated tablets

DRUGJNJ-75276617 (G008)

DRUGCYTARABINE ACCORD 100 mg/ml

DRUGsolution injectable ou pour perfusion

DRUGJNJ-75276617 (G024)

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Incidence and severity of AEs, including DLTs, 2. Incidence and severity of Aes	—

Countries

France, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026